Media Statements

Ipsen media statements for investors and members of the press.

Key highlights

Explore more statements

Filter

Topics

Period

Filter by

recent search

Reset

Showing: 1 – 05 of 4 Media Statements

Ipsen CEO David Loew is elected to EFPIA leadership; joins industry partners to warn of impact of EU pharma legislation
Statement Document Icon  –  22 June 2023

22 June 2023

Ipsen CEO David Loew is elected to EFPIA leadership; joins industry partners to warn of impact of EU pharma legislation

On Wednesday 21 June, David Loew was elected second Vice President of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Yesterday’s appointments also included Lars Fruergaard Jørgensen, Chief Executive of Novo Nordisk, as EFPIA President, and Stefan Oelrich, Head…


Ipsen and Medetia join forces to accelerate early research in rare disease
Statement Document Icon  –  06 June 2023

06 June 2023

Ipsen and Medetia join forces to accelerate early research in rare disease


Ipsen Announces Decision to Permanently Discontinue Distribution of NutropinAq® (somatropin) cartridges
Statement Document Icon  –  24 April 2023

24 April 2023

Ipsen Announces Decision to Permanently Discontinue Distribution of NutropinAq® (somatropin) cartridges

Ipsen is committed to bringing innovative medicines to the rare disease community where a significant unmet need exists and innovation in treatments is lacking.


Offering support to those impacted in Turkey & Syria
Statement Document Icon  –  20 February 2023

20 February 2023

Offering support to those impacted in Turkey & Syria

We are deeply saddened by the tragic earthquake across Turkey and Syria and the worsening humanitarian crisis. Our thoughts are with all of those impacted by the devastating events and our gratitude to those who are bravely leading the rescue…


Your dedicated contacts

Related links